{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:44:47Z","timestamp":1791305087988,"version":"4.3.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2013,8,14]],"date-time":"2013-08-14T00:00:00Z","timestamp":1376438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2013,8,14]],"date-time":"2013-08-14T00:00:00Z","timestamp":1376438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1007\/s11912-013-0332-6","type":"journal-article","created":{"date-parts":[[2013,8,13]],"date-time":"2013-08-13T12:19:16Z","timestamp":1376396356000},"page":"457-464","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Therapeutic Options for Adult T-Cell Leukemia\/Lymphoma"],"prefix":"10.1007","volume":"15","author":[{"given":"Ambroise","family":"Mar\u00e7ais","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Suarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Sibon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Frenzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Hermine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Bazarbachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,8,14]]},"reference":[{"key":"332_CR1","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/j.1365-2141.1991.tb08051.x","volume":"79","author":"M Shimoyama","year":"1991","unstructured":"Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984\u201387). Br J Haematol. 1991;79:428\u201337.","journal-title":"Br J Haematol"},{"key":"332_CR2","doi-asserted-by":"crossref","unstructured":"\u2022 Tsukasaki K et al. Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. J Clin Oncol. 2009;27:453\u20139. This paper describes consensus diagnosis criteria and Treatment of HTLV-1 related lymphoproliferation.","DOI":"10.1200\/JCO.2008.18.2428"},{"key":"332_CR3","first-page":"932175","volume":"2012","author":"A Mar\u00e7ais","year":"2012","unstructured":"Mar\u00e7ais A, Suarez F, Sibon D, Bazarbachi A, Hermine O. Clinical trials of adult T-cell leukaemia\/lymphoma treatment. Leuk Res Treat. 2012;2012:932175.","journal-title":"Leuk Res Treat"},{"key":"332_CR4","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1182\/blood-2009-09-242347","volume":"115","author":"Y Takasaki","year":"2010","unstructured":"Takasaki Y et al. Long-term study of indolent adult T-cell leukemia-lymphoma. Blood. 2010;115:433.","journal-title":"Blood"},{"key":"332_CR5","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1200\/JCO.1988.6.7.1088","volume":"6","author":"M Shimoyama","year":"1988","unstructured":"Shimoyama M et al. Major prognostic factors of adult patients with advanced T-cell lymphoma\/leukemia. J Clin Oncol. 1988;6:1088\u201397.","journal-title":"J Clin Oncol"},{"key":"332_CR6","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1007\/BF02983215","volume":"77","author":"K Tsukasaki","year":"2003","unstructured":"Tsukasaki K et al. Deoxycoformycin-containing combination chemotherapy for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study (JCOG9109). Int J Hematol. 2003;77:164\u201370.","journal-title":"Int J Hematol"},{"key":"332_CR7","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1046\/j.1365-2141.2001.02737.x","volume":"113","author":"Y Yamada","year":"2001","unstructured":"Yamada Y et al. A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303. Br J Haematol. 2001;113:375\u201382.","journal-title":"Br J Haematol"},{"key":"332_CR8","doi-asserted-by":"publisher","first-page":"5458","DOI":"10.1200\/JCO.2007.11.9958","volume":"25","author":"K Tsukasaki","year":"2007","unstructured":"Tsukasaki K et al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol. 2007;25:5458\u201364.","journal-title":"J Clin Oncol"},{"key":"332_CR9","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1182\/blood-2009-10-247510","volume":"116","author":"M Hishizawa","year":"2010","unstructured":"Hishizawa M et al. Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study. Blood. 2010;116:1369.","journal-title":"Blood"},{"key":"332_CR10","doi-asserted-by":"publisher","first-page":"A33","DOI":"10.1186\/1742-4690-8-S1-A33","volume":"8","author":"N Uike","year":"2011","unstructured":"Uike N, Tanosaki R, Utsunomiya A, Choi I, Okamura J. Can allo-SCT with RIC cure ATLL? long-term survivors with excellent PS and with heterogenous HTLV-1 proviral load level. Retrovirology. 2011;8:A33.","journal-title":"Retrovirology"},{"key":"332_CR11","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1182\/blood-2012-07-444372","volume":"121","author":"H Itonaga","year":"2013","unstructured":"Itonaga H et al. Treatment of relapsed adult T-cell leukemia\/lymphoma after allogeneic hematopoietic stem cell transplantation: the Nagasaki Transplant Group experience. Blood. 2013;121:219\u201325.","journal-title":"Blood"},{"key":"332_CR12","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1182\/blood-2011-07-368233","volume":"119","author":"J Kanda","year":"2012","unstructured":"Kanda J et al. Impact of graft-versus-host disease on outcomes after allogeneic hematopoietic cell transplantation for adult T-cell leukemia: a retrospective cohort study. Blood. 2012;119:2141\u20138.","journal-title":"Blood"},{"key":"332_CR13","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1056\/NEJM199506293322603","volume":"332","author":"PS Gill","year":"1995","unstructured":"Gill PS et al. Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N Engl J Med. 1995;332:1744\u20138.","journal-title":"N Engl J Med"},{"key":"332_CR14","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJM199506293322604","volume":"332","author":"O Hermine","year":"1995","unstructured":"Hermine O et al. Brief report: treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon alfa. N Engl J Med. 1995;332:1749\u201351.","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"332_CR15","doi-asserted-by":"publisher","first-page":"S186","DOI":"10.1097\/00042560-199600001-00028","volume":"13","author":"A Bazarbachi","year":"1996","unstructured":"Bazarbachi A, Hermine O. Treatment with a combination of zidovudine and alpha-interferon in naive and pretreated adult T-cell leukemia\/lymphoma patients. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13 Suppl 1:S186\u201390.","journal-title":"J Acquir Immune Defic Syndr Hum Retrovirol"},{"key":"332_CR16","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/sj.thj.6200195","volume":"3","author":"O Hermine","year":"2002","unstructured":"Hermine O et al. A prospective phase II clinical trial with the use of zidovudine and interferon-alpha in the acute and lymphoma forms of adult T-cell leukemia\/lymphoma. Hematol J. 2002;3:276\u201382.","journal-title":"Hematol J"},{"key":"332_CR17","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3109\/10428190109057927","volume":"40","author":"JD White","year":"2001","unstructured":"White JD et al. The combination of zidovudine and interferon alpha-2B in the treatment of adult T-cell leukemia\/lymphoma. Leuk Lymphoma. 2001;40:287\u201394.","journal-title":"Leuk Lymphoma"},{"key":"332_CR18","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Bazarbachi A et al. Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia\/lymphoma showing improved survival in the leukemic subtypes. J Clin Oncol. 2010;28:4177\u201383. This paper reports the efficacy of the combination of anti-retroviral therapy in all subtypes of ATLL except lymphoma subtype. Data are based on a retrospective analysis of a large series of patients from France, UK and US.","DOI":"10.1200\/JCO.2010.28.0669"},{"key":"332_CR19","doi-asserted-by":"publisher","first-page":"750","DOI":"10.3390\/v3060750","volume":"3","author":"R Nasr","year":"2011","unstructured":"Nasr R et al. Controversies in targeted therapy of adult T cell leukemia\/lymphoma: om target or off target effects? Viruses. 2011;3:750\u201369.","journal-title":"Viruses"},{"key":"332_CR20","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1182\/blood-2006-01-0067","volume":"108","author":"A Datta","year":"2006","unstructured":"Datta A et al. Persistent inhibition of telomerase reprograms adult T-cell leukemia to p53-dependent senescence. Blood. 2006;108:1021\u20139.","journal-title":"Blood"},{"issue":"21","key":"332_CR21","doi-asserted-by":"crossref","first-page":"Abstr 3961","DOI":"10.1182\/blood.V116.21.3961.3961","volume":"116","author":"A Hodson","year":"2010","unstructured":"Hodson A et al. Addition of anti-viral therapy to chemotherapy improves overall survival in acute and lymphomatous adult T-cell leukaemia\/lymphoma (ATLL). Blood. 2010;116(21):Abstr 3961.","journal-title":"Blood"},{"key":"332_CR22","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1182\/blood.V93.1.278","volume":"93","author":"A Bazarbachi","year":"1999","unstructured":"Bazarbachi A et al. Arsenic trioxide and interferon-alpha synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic virus type I-transformed cells. Blood. 1999;93:278\u201383.","journal-title":"Blood"},{"key":"332_CR23","first-page":"2849","volume":"96","author":"ME El-Sabban","year":"2000","unstructured":"El-Sabban ME et al. Arsenic-interferon-alpha-triggered apoptosis in HTLV-I transformed cells is associated with tax down-regulation and reversal of NF-kappa B activation. Blood. 2000;96:2849\u201355.","journal-title":"Blood"},{"key":"332_CR24","doi-asserted-by":"publisher","first-page":"4576","DOI":"10.1182\/blood-2002-09-2986","volume":"101","author":"R Nasr","year":"2003","unstructured":"Nasr R et al. Arsenic\/interferon specifically reverses 2 distinct gene networks critical for the survival of HTLV-1-infected leukemic cells. Blood. 2003;101:4576\u201382.","journal-title":"Blood"},{"key":"332_CR25","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1084\/jem.20101095","volume":"207","author":"H El Hajj","year":"2010","unstructured":"El Hajj H et al. Therapy-induced selective loss of leukemia-initiating activity in murine adult T cell leukemia. J Exp Med. 2010;207:2785\u201392.","journal-title":"J Exp Med"},{"key":"332_CR26","doi-asserted-by":"publisher","first-page":"6528","DOI":"10.1182\/blood-2009-03-211821","volume":"113","author":"G Kchour","year":"2009","unstructured":"Kchour G et al. Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia\/lymphoma (ATL). Blood. 2009;113:6528\u201332.","journal-title":"Blood"},{"key":"332_CR27","doi-asserted-by":"publisher","first-page":"A59","DOI":"10.1186\/1742-4690-8-S1-A59","volume":"8","author":"F Suarez","year":"2011","unstructured":"Suarez F et al. Arsenic trioxyde in the treatment of HTLV1 associated ATLL. Retrovirology. 2011;8:A59.","journal-title":"Retrovirology"},{"key":"332_CR28","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1182\/blood.V82.6.1701.1701","volume":"82","author":"TA Waldmann","year":"1993","unstructured":"Waldmann TA et al. The interleukin-2 receptor: a target for monoclonal antibody treatment of human T-cell lymphotrophic virus I-induced adult T-cell leukemia. Blood. 1993;82:1701\u201312.","journal-title":"Blood"},{"key":"332_CR29","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.1182\/blood.V86.11.4063.bloodjournal86114063","volume":"86","author":"TA Waldmann","year":"1995","unstructured":"Waldmann TA et al. Radioimmunotherapy of interleukin-2R alpha-expressing adult T-cell leukemia with yttrium-90-labeled anti-Tac. Blood. 1995;86:4063\u201375.","journal-title":"Blood"},{"key":"332_CR30","doi-asserted-by":"publisher","first-page":"A60","DOI":"10.1186\/1742-4690-8-S1-A60","volume":"8","author":"I Moura","year":"2011","unstructured":"Moura I et al. A neutralizing monoclonal antibody (mAb A24) directed against the transferrin receptor induces apoptosis of tumor T lymphocytes from ATL patients. Retrovirology. 2011;8:A60.","journal-title":"Retrovirology"},{"key":"332_CR31","doi-asserted-by":"publisher","first-page":"A40","DOI":"10.1186\/1742-4690-8-S1-A40","volume":"8","author":"A Utsunomiya","year":"2011","unstructured":"Utsunomiya A et al. Promising results of an anti-CCR4 antibody, KW-0761, for relapsed adult T-cell leukemia-lymphoma (ATL). Retrovirology. 2011;8:A40.","journal-title":"Retrovirology"},{"key":"332_CR32","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1200\/JCO.2011.37.3472","volume":"30","author":"T Ishida","year":"2012","unstructured":"Ishida T et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol. 2012;30:837\u201342.","journal-title":"J Clin Oncol"},{"key":"332_CR33","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1200\/JCO.2006.10.2434","volume":"25","author":"EA Olsen","year":"2007","unstructured":"Olsen EA et al. Phase IIB multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007;25:3109\u201315.","journal-title":"J Clin Oncol"},{"key":"332_CR34","doi-asserted-by":"publisher","first-page":"4485","DOI":"10.1200\/JCO.2010.28.9066","volume":"28","author":"SJ Whittaker","year":"2010","unstructured":"Whittaker SJ et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol. 2010;28:4485\u201391.","journal-title":"J Clin Oncol"},{"key":"332_CR35","doi-asserted-by":"publisher","first-page":"5827","DOI":"10.1182\/blood-2010-10-312603","volume":"117","author":"RL Piekarz","year":"2011","unstructured":"Piekarz RL et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood. 2011;117:5827.","journal-title":"Blood"},{"key":"332_CR36","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","volume":"30","author":"B Coiffier","year":"2012","unstructured":"Coiffier B et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol. 2012;30:631\u20136.","journal-title":"J Clin Oncol"},{"key":"332_CR37","doi-asserted-by":"publisher","first-page":"A48","DOI":"10.1186\/1742-4690-8-S1-A48","volume":"8","author":"J Ramos","year":"2011","unstructured":"Ramos J et al. Targeting HTLV-I latency in adult T-cell leukemia\/lymphoma. Retrovirology. 2011;8:A48.","journal-title":"Retrovirology"},{"key":"332_CR38","doi-asserted-by":"publisher","first-page":"3802","DOI":"10.1182\/blood-2010-02-270751","volume":"116","author":"PV Afonso","year":"2010","unstructured":"Afonso PV et al. Highly active antiretroviral treatment against STLV-1 infection combining reverse transcriptase and HDAC inhibitors. Blood. 2010;116:3802\u20138.","journal-title":"Blood"},{"key":"332_CR39","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1182\/blood.V98.6.1721","volume":"98","author":"CE Dearden","year":"2001","unstructured":"Dearden CE et al. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood. 2001;98:1721\u20136.","journal-title":"Blood"},{"key":"332_CR40","doi-asserted-by":"publisher","first-page":"3380","DOI":"10.1182\/blood-2005-01-0335","volume":"106","author":"A Mone","year":"2005","unstructured":"Mone A et al. Durable hematologic complete response and suppression of HTLV-1 viral load following alemtuzumab in zidovudine\/IFN-a-refractory adult T-cell leukemia. Blood. 2005;106:3380\u20132.","journal-title":"Blood"},{"key":"332_CR41","doi-asserted-by":"publisher","first-page":"5425","DOI":"10.1200\/JCO.2009.22.6688","volume":"27","author":"F Ravandi","year":"2009","unstructured":"Ravandi F et al. Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms. J Clin Oncol. 2009;27:5425\u201330.","journal-title":"J Clin Oncol"},{"key":"332_CR42","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1111\/j.1349-7006.2009.01354.x","volume":"101","author":"N Maeda","year":"2010","unstructured":"Maeda N, Muta H, Oflazoglu E, Yoshikai Y. Susceptibility of human T-cell leukemia virus type I-infected cells to humanized anti-CD30 monoclonal antibodies in vitro and in vivo. Cancer Sci. 2010;101:224\u201330.","journal-title":"Cancer Sci"},{"key":"332_CR43","doi-asserted-by":"publisher","first-page":"3963","DOI":"10.1073\/pnas.92.9.3963","volume":"92","author":"JM Flaman","year":"1995","unstructured":"Flaman JM et al. A simple p53 functional assay for screening cell lines, blood, and tumors. Proc Natl Acad Sci U S A. 1995;92:3963\u20137.","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-013-0332-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-013-0332-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-013-0332-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-013-0332-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T10:56:45Z","timestamp":1659092205000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-013-0332-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,14]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["332"],"URL":"https:\/\/doi.org\/10.1007\/s11912-013-0332-6","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,14]]},"assertion":[{"value":"14 August 2013","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}